Company: MLSS
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001493152-25-022276
Chunk: 44

Company: MILESTONE SCIENTIFIC INC.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 1
Chunk 44
---
 $4,783,111  
    $4,859,275  
    $(76,164)
  
    Medical 
     122,800  
     64,251  
     58,549 
  
    Total gross profit 
    $4,905,911  
    $4,923,526  
    $(17,615)

Consolidated gross profit for the nine months ended September 30, 2025,
and 2024 was approximately $4.9 million for each period, reflecting no material change year over year. Stable gross profit performance
was primarily the result of consistent product margins, favorable manufacturing cost management, and a balanced sales mix between domestic
and international markets.

Despite modest fluctuations in regional and product-level revenue, the
Company maintained gross margin stability through ongoing operational efficiencies, disciplined pricing strategies, and continued supply
chain optimization.

Selling,
general and administrative expenses for 2025 and 2024 were as follows: 

    2025  
    2024  
    Change 
  
    Dental 
    $3,027,615  
    $2,695,029  
    $332,586 
  
    Medical 
     1,234,199  
     1,411,053  
     (176,854)
  
    Corporate 
     4,764,877  
     4,862,144  
     (97,267)
  
    Total selling, general and administrative expenses 
    $9,026,691  
    $8,968,226  
    $58,465 

Consolidated selling, general, and administrative (SG&A) expenses for
the nine months ended September 30, 2025, and 2024 were approximately $9.0 million in both periods, reflecting a slight net increase of
approximately $58,000 year over year. The modest change primarily resulted from higher consulting, professional, and regulatory expenses
totaling approximately $611,000, which were largely offset by reductions in employee salaries and benefits, marketing, warehousing, and
travel expenses amounting to approximately $552,000.

The overall stability in SG&A spending demonstrates management’s
ongoing focus on expense control, operational efficiency, and resource optimization, while continuing to support the Company’s commercial
initiatives and regulatory compliance activities

Research
and Development for 2025 and 2024 were as follows: